Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden

April 1, 2016 at 8:12 am

European Respiratory Journal April 2016 V.47 N.4 P.1208-1218

Ilias Galanis, Ann Lindstrand, Jessica Darenberg, Sarah Browall, Priyanka Nannapaneni, Karin Sjöström, Eva Morfeldt, Pontus Naucler, Margareta Blennow, Åke Örtqvist, Birgitta Henriques-Normark

The effects of pneumococcal conjugated vaccines (PCVs) need to be investigated. In Stockholm County, Sweden, PCV7 was introduced in the childhood immunisation programme in 2007 and changed to PCV13 in 2010.

Over 90% of all invasive isolates during 2005–2014 (n=2336) and carriage isolates, 260 before and 647 after vaccine introduction, were characterised by serotyping, molecular typing and antibiotic susceptibility, and serotype diversity was calculated. Clinical information was collected for children and adults with invasive pneumococcal disease (IPD).

The IPD incidence decreased post-PCV7, but not post-PCV13, in vaccinated children. Beneficial herd effects were seen in older children and adults, but not in the elderly. The herd protection was more pronounced post-PCV7 than post-PCV13. PCV7 serotypes decreased. IPD caused by PCV13 serotypes 3 and 19A increased post-PCV7. Post-PCV13, serotypes 6A and 19A, but not serotype 3, decreased. The serotype distribution changed in carriage and IPD to nonvaccine types, also in nonvaccinated populations. Expansion of non-PCV13 serotypes was largest following PCV13 introduction. Serotype diversity increased and nonvaccine clones emerged, such as CC433 (serotype 22F) in IPD and CC62 (serotype 11A) in carriage. In young children, meningitis, septicaemia and severe rhinosinusitis, but not bacteraemic pneumonia, decreased.



Entry filed under: Epidemiología, Inmunizaciones.

Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands


April 2016
« Mar   May »

Most Recent Posts

%d bloggers like this: